Dr Ryan Anderton

BForensics, BSc (Hons), PhD (Neuroscience) 
Associate Professor; Deputy Head of School, Health Sciences

Email: ryan.anderton@nd.edu.au
Phone: 9433 0670

  • Biography

    Ryan is the Discipline lead of Biomedical Science and the current Deputy Head of the School of Health Sciences. He completed his PhD in Neuroscience at UWA and has since gained significant experience in tertiary education, academic leadership, and biomedical research. Ryan leads a multi-disciplinary research team focussing on Neurodegeration and the contribution of the gut in neurological disease and function.

  • Teaching Areas

    • Anatomy and physiology
    • Neuroscience
    • Human genetics
    • Research skills and data analysis

  • Research Expertise and Supervision

    Ryan leads a multi-disciplinary research group investigating the role of the gut brain axis in aging and neurodegenerative disease. He has a strong track record of publications and obtaining competitive funding. Ryan is currently involved in a range of clinical and pre-clinical projects, with a strong focus on Parkinson’s disease. He has supervised more than 50 Honours students and 7 PhD students. He currently supervises 5 PhD students, several Masters, and Honours students.

  • Book Chapters

    • Kenna, J., & Anderton, R. S. (2020). The role of the gastrointestinal system and gut microbiota in Parkinson's disease. In Genetics, Neurology, Behavior, and Diet in Parkinson's Disease (pp. 569-582). Academic Press.
    • Bakeberg, M., Riley, M., Byrnes, M., Mastaglia, F. L., & Anderton, R. S. (2020). Clinically assessing cognitive function in Parkinson's disease. In Diagnosis and Management in Parkinson's Disease (pp. 409-423). Academic Press.

  • Journal Articles and Proceedings

    • Jeyadevan, A., Bakeberg, M. C., Byrnes, M., Kenna, J. E., McGregor, S.,Ghosh, S., Horne, M. K., Stell, R., Evans, T. Mastaglia, F. L., & Anderton, R. S. (2023). Quality of life implications for elevated trait impulsivity in people with Parkinson’s disease. Quality of life research.
    • Spencer, H., Gorecki, A., Foley, H., Phillips, L., Abonnel, A., Meloni, B., Anderton, R.S. (2023). Poly- arginine R18 peptide inhibits heat-induced lysozyme protein aggregation: Implications for a possible therapeutic role in Parkinson’s disease. Applied Biochemistry and Microbiology, 59(1), 44-51. https://doi.org/10.1134/S0003683823010118
    • Chiu, L. S., & Anderton, R. S. (2022). The role of the microbiota-gut-brain axis in long-term neurodegenerative processes following traumatic brain injury. European Journal of Neuroscience.
    • Kenna, J. E., Bakeberg, M. C., Abonnel, M. Y., Mastaglia, F. L., & Anderton, R. S. (2022). Impact of Gastrointestinal Symptoms on Health-Related Quality of Life in an Australian Parkinson’s Disease Cohort. Parkinson’s Disease, 2022.
    • Theunissen, F., Flynn, L. L., Anderton, R. S., & Akkari, P. A. (2022). Short structural variants as informative genetic markers for ALS disease risk and progression. BMC medicine, 20(1), 1-7.
    • Theunissen, F., Anderton, R. S., Mastaglia, F. L., James, I., Bedlack, R., & Akkari, P. A. (2022). Intronic NEFH variant is associated with reduced risk for sporadic ALS and later age of disease onset.
    • Seewoo, B. J., Chua, E. G., Arena-Foster, Y., Hennessy, L. A., Gorecki, A. M., Anderton, R., & Rodger, J. (2022). Changes in the rodent gut microbiome following chronic restraint stress and low-intensity rTMS. Neurobiology of stress, 17, 100430.
    • Jacob, Y., Hart, N. H., Cochrane, J. L., Spiteri, T., Laws, S. M., Jones, A., Rogalski, B., Kenna, J., & Anderton, R. S. (2022). ACTN3 (R577X) Genotype is associated with Australian Football League Players. Journal of strength and conditioning research, 36(2), 573-576.
    • Jacob, Y., Anderton, R. S., Cochrane Wilkie, J. L., Rogalski, B., Laws, S. M., Jones, A., Spiteri, T., Hince, D., & Hart, N. H. (2022). Genetic variants within NOGGIN, COL1A1, COL5A1, and IGF2 are associated with musculoskeletal injuries in elite male Australian Football League players: a preliminary study. Sports Medicine-Open, 8(1), 1-14.
    • Grant, H., Anderton, R., Gasson, N., & Lawrence, B. J. (2022). The gut microbiome and cognition in Parkinson’s disease: a systematic review. Nutritional Neuroscience, 1-10.
    • Evans, T., Ali, U., Anderton, R., Raby, E., Manning, L., & Litton, E. (2022). Lower gut dysbiosis and mortality in acute critical illness: a systematic review and meta-analysis.
    • Anyaegbu, C. C., Szemray, H., Hellewell, S. C., Lawler, N. G., Leggett, K., Bartlett, C., Lins, B., McGonigle, T., Papini, M., Anderton, R. S., Whiley, L., Fitzgerald, M. (2022). Plasma Lipid Profiles Change with Increasing Numbers of Mild Traumatic Brain Injuries in Rats. Metabolites, 12(4), 322.
    • Theunissen, F., Anderton, R. S., Mastaglia, F. L., Flynn, L. L., Winter, S. J., James, I., Bedlack, R., Hodgetts, S., Fletcher, S., & Wilton, S. D. (2021). Novel STMN2 variant linked to amyotrophic lateral sclerosis risk and clinical phenotype. Frontiers in Aging Neuroscience, 13, 658226.
    • Theunissen, F., Akkari, P. A., Flynn, L., & Anderton, R. (2021). A BIOMARKER AND USES THEREFOR. In: WO Patent WO / 2021/108,869.
    • Milani, D., Clark, V. W., Feindel, K. W., Blacker, D. J., Bynevelt, M., Edwards, A. B., Anderton, R. S., Knuckey, N. W., & Meloni, B. P. (2021). Comparative assessment of the proteolytic stability and impact of poly-arginine peptides R18 and R18D on infarct growth and penumbral tissue preservation following middle cerebral artery occlusion in the Sprague Dawley rat. Neurochemical Research, 46(5), 1166-1176.
    • Kenna, J. E., Chua, E. G., Bakeberg, M. C., Tay, A., Mcgregor, S., Gorecki, A. M., Horne, M., Marshall, B., Mastaglia, F. L., & Anderton, R. S. (2021). Changes in the gut microbiome and predicted functional metabolic effects in an Australian Parkinson's disease cohort. Frontiers in neuroscience, 1412.
    • Kenna, J. E., Bakeberg, M. C., Gorecki, A. M., Chin Yen Tay, A., Winter, S., Mastaglia, F. L., & Anderton, R. S. (2021). Characterization of gastrointestinal symptom type and severity in Parkinson's disease: a case–control study in an Australian cohort. Movement disorders clinical practice, 8(2), 245-253.
    • Jacob, Y., Anderton, R. S., Cochrane Wilkie, J. L., Rogalski, B., Laws, S. M., Jones, A., Spiteri, T., & Hart, N. H. (2021). Association of genetic variances in ADRB1 and PPARGC1a with two-kilometre running time-trial performance in Australian Football League players: a preliminary study. Sports, 9(2), 22.
    • Gorecki, A. M., Anyaegbu, C. C., & Anderton, R. S. (2021). TLR2 and TLR4 in Parkinson’s disease pathogenesis: the environment takes a toll on the gut. Translational Neurodegeneration, 10(1), 1-19.
    • Bakeberg, M. C., Hoes, M. E., Gorecki, A. M., Theunissen, F., Pfaff, A. L., Kenna, J. E., Plunkett, K., Kõks, S., Akkari, P. A., Mastaglia, F. L., Anderton, R.S. (2021). The TOMM40 ‘523’polymorphism in disease risk and age of symptom onset in two independent cohorts of Parkinson’s disease. Scientific Reports, 11(1), 1-9.
    • Bakeberg, M. C., Gorecki, A. M., Pfaff, A. L., Hoes, M. E., Kõks, S., Akkari, P. A., Mastaglia, F. L., & Anderton, R. S. (2021). TOMM40 ‘523’poly-T repeat length is a determinant of longitudinal cognitive decline in Parkinson’s disease. npj Parkinson's Disease, 7(1), 1-9.
    • Bakeberg, M. C., Gorecki, A. M., Kenna, J. E., Jefferson, A., Byrnes, M., Ghosh, S., Horne, M. K., McGregor, S., Stell, R., Walters, S., Mastaglia, F. L., & Anderton, R. S. (2021). Elevated HDL levels linked to poorer cognitive ability in females with Parkinson’s disease. Frontiers in Aging Neuroscience, 13, 287.
    • Bakeberg, M. C., Gorecki, A. M., Kenna, J. E., Jefferson, A., Byrnes, M., Ghosh, S., Horne, M. K., McGregor, S., Stell, R., Walters, S., Chivers, P., Winter, S., Mastaglia, F. L., & Anderton, R. S. (2021). Differential effects of sex on longitudinal patterns of cognitive decline in Parkinson’s disease. Journal of Neurology, 1-10.
    • Anderton, R. S., Vitali, J., Blackmore, C., & Bakeberg, M. C. (2021). Flexible teaching and learning modalities in undergraduate science amid the covid-19 pandemic.. Frontiers in Education, 5.
    • Vitali, J., Blackmore, C., Mortazavi, S., & Anderton, R. (2020). Tertiary Anatomy and Physiology, a Barrier for Student Success. International Journal of Higher Education, 9(2), 289-296.
    • Theunissen, F., Flynn, L. L., Anderton, R. S., Mastaglia, F., Pytte, J., Jiang, L., Hodgetts, S., Burns, D. K., Saunders, A., & Fletcher, S. (2020). Structural variants may be a source of missing heritability in sALS. Frontiers in neuroscience, 14, 47.
    • Pytte, J., Flynn, L. L., Anderton, R. S., Mastaglia, F. L., Theunissen, F., James, I., Pfaff, A., Koks, S., Saunders, A. M., & Bedlack, R. (2020). Disease-modifying effects of an SCAF4 structural variant in a predominantly SOD1 ALS cohort. Neurology Genetics, 6(4).
    • Pytte, J., Anderton, R. S., Flynn, L. L., Theunissen, F., Jiang, L., Pitout, I., James, I., Mastaglia, F. L., Saunders, A. M., & Bedlack, R. (2020). Association of a structural variant within the SQSTM1 gene with amyotrophic lateral sclerosis. Neurology Genetics, 6(2).
    • Meloni, B. P., Chen, Y., Harrison, K. A., Nashed, J. Y., Blacker, D. J., South, S. M., Anderton, R. S., Mastaglia, F. L., Winterborn, A., & Knuckey, N. W. (2020). Poly-arginine peptide-18 (R18) reduces brain injury and improves functional outcomes in a nonhuman primate stroke model. Neurotherapeutics, 17(2), 627-634.
    • MacDougall, G., Anderton, R. S., Trimble, A., Mastaglia, F. L., Knuckey, N. W., & Meloni, B. P. (2020). Poly-arginine-18 (R18) confers neuroprotection through glutamate receptor modulation, intracellular calcium reduction, and preservation of mitochondrial function. Molecules, 25(13), 2977.
    • MacDougall, G., Anderton, R. S., Ouliel, E., Gao, J., Redmond, S. L., Knuckey, N. W., & Meloni, B. P. (2020). In vitro cellular uptake and neuroprotective efficacy of poly-arginine-18 (R18) and poly-ornithine-18 (O18) peptides: critical role of arginine guanidinium head groups for neuroprotection. Molecular and Cellular Biochemistry, 464(1), 27-38.
    • Kenna, J. E., Anderton, R. S., Knuckey, N. W., & Meloni, B. P. (2020). Assessment of recombinant tissue plasminogen activator (rtPA) toxicity in cultured neural cells and subsequent treatment with poly-arginine peptide R18D. Neurochemical Research, 45(5), 1215-1229.
    • Gorecki, A. M., Dunlop, S. A., Rodger, J., & Anderton, R. S. (2020). The gut-brain axis and gut inflammation in Parkinson’s disease: stopping neurodegeneration at the toll gate. Expert opinion on therapeutic targets, 24(7), 601-604.
    • Gorecki, A. M., Bakeberg, M. C., Theunissen, F., Kenna, J. E., Hoes, M. E., Pfaff, A. L., Akkari, P. A., Dunlop, S. A., Kõks, S., Mastaglia, F. L., Anderton, R.S. (2020). Single nucleotide polymorphisms associated with gut homeostasis influence risk and age-at-onset of Parkinson's disease. Frontiers in Aging Neuroscience, 12, 603849.
    • Chiu, L. S., Anderton, R. S., Clark, V. W., Knuckey, N. W., Mardon, K., Bhalla, R., South, S. M., & Meloni, B. P. (2020). Tissue distribution of intravenously administrated poly-arginine peptide R18D in healthy male Sprague–Dawley rats. Future Drug Discovery, 2(2), FDD37.
    • Chiu, L. S., Anderton, R. S., Clark, V. W., Cross, J. L., Knuckey, N. W., & Meloni, B. P. (2020). Effect of polyarginine peptide R18D following a traumatic brain injury in Sprague-Dawley rats. Current Therapeutic Research, 92, 100584.
    • Blackmore, C., Hird, K., & Anderton, R. S. (2020). An Investigation of Secondary School STEM Subjects as Predictors of Academic Performance in Tertiary Level Health Sciences Programs. International Journal of Higher Education, 10(1), 2021.
    • Bakeberg, M. C., Riley, M., Byrnes, M., Jefferson, A., Ghosh, S., Horne, M. K., McGregor, S., Stell, R., Walters, S., Evans, T., Roberts, K., Mastaglia, F. L., & Anderton, R. S. (2020). Elevated serum ceruloplasmin levels are associated with higher impulsivity in people with parkinson’s disease. Parkinson’s Disease, 2020.
    • MacDougall, G., Anderton, R. S., Mastaglia, F. L., Knuckey, N. W., & Meloni, B. P. (2019). Proteomic analysis of cortical neuronal cultures treated with poly-arginine peptide-18 (R18) and exposed to glutamic acid excitotoxicity. Molecular brain, 12(1), 1-16.
    • MacDougall, G., Anderton, R. S., Mastaglia, F. L., Knuckey, N. W., & Meloni, B. P. (2019). Mitochondria and neuroprotection in stroke: Cationic arginine-rich peptides (CARPs) as a novel class of mitochondria-targeted neuroprotective therapeutics. Neurobiology of Disease, 121, 17-33.
    • Jeyadevan, A., Bakeberg, M. C., Byrnes, M., Kenna, J., Ghosh, S., Stell, R., Walters, S., Evans, T., McGregor, S., Horne, M., Mastaglia, F. L., & Anderton, R. S. (2019). Trait impulsivity is independent of mild cognitive impairment in a Parkinson’s disease cohort. Parkinson’s Disease, 2019.
    • Jacob, Y., Chivers, P., & Anderton, R. S. (2019). Genetic predictors of match performance in sub-elite Australian football players: A pilot study. Journal of Exercise Science & Fitness, 17(2), 41-46.
    • Gorecki, A. M., Preskey, L., Bakeberg, M. C., Kenna, J. E., Gildenhuys, C., MacDougall, G., Dunlop, S. A., Mastaglia, F. L., Akkari, P. A., Koengten, F., Anderton, R.S. (2019). Altered gut microbiome in Parkinson’s disease and the influence of lipopolysaccharide in a human α-synuclein over-expressing mouse model. Frontiers in neuroscience, 13, 839.
    • Flora, G. K., Anderton, R. S., Meloni, B. P., Guillemin, G. J., Knuckey, N. W., MacDougall, G., Matthews, V., & Boulos, S. (2019). Microglia are both a source and target of extracellular cyclophilin A. Heliyon, 5(9), e02390.
    • Chiu, L. S., Anderton, R. S., Cross, J. L., Clark, V. W., Knuckey, N. W., & Meloni, B. P. (2019). Poly-arginine peptide R18D reduces neuroinflammation and functional deficits following traumatic brain injury in the long-evans rat. International Journal of Peptide Research and Therapeutics, 25(4), 1563-1572.
    • Bakeberg, M. C., Jefferson, A., Riley, M., Byrnes, M., Ghosh, S., Mastaglia, F. L., Horne, M. K., McGregor, S., Stell, R., Kenna, J., Walters, S., Hince, D., Anderton, R.S. (2019). Elevated serum homocysteine levels have differential gender-specific associations with motor and cognitive states in Parkinson’s disease. Parkinson’s Disease, 2019.
    • Riley, M., Bakeberg, M., Byrnes, M., Jefferson, A., Ghosh, S., Stell, R., Mastaglia, F. L., Hince, D., & Anderton, R. S. (2018). Demographic and clinical predictors of trait impulsivity in Parkinson’s disease patients. Parkinson’s Disease, 2018.
    • Milani, D., Bakeberg, M. C., Cross, J. L., Clark, V. W., Anderton, R. S., Blacker, D. J., Knuckey, N. W., & Meloni, B. P. (2018). Comparison of neuroprotective efficacy of poly-arginine R18 and R18D (D-enantiomer) peptides following permanent middle cerebral artery occlusion in the Wistar rat and in vitro toxicity studies. PloS one, 13(3), e0193884.
    • Jacob, Y., Spiteri, T., Hart, N. H., & Anderton, R. S. (2018). The potential role of genetic markers in talent identification and athlete assessment in elite sport. Sports, 6(3), 88.
    • Edwards, A. B., Cross, J. L., Anderton, R. S., Knuckey, N. W., & Meloni, B. P. (2018). Poly-arginine R18 and R18D (D-enantiomer) peptides reduce infarct volume and improves behavioural outcomes following perinatal hypoxic-ischaemic encephalopathy in the P7 rat. Molecular brain, 11(1), 1-12.
    • Edwards, A. B., Anderton, R. S., Knuckey, N. W., & Meloni, B. P. (2018). Assessment of therapeutic window for poly-arginine-18D (R18D) in a P7 rat model of perinatal hypoxic-ischaemic encephalopathy. Journal of Neuroscience Research, 96(11), 1816-1826.
    • Edwards, A. B., Anderton, R. S., Knuckey, N. W., & Meloni, B. P. (2018). Perinatal hypoxic-ischemic encephalopathy and neuroprotective peptide therapies: A case for cationic arginine-rich peptides (CARPs). Brain Sciences, 8(8), 147.
    • Milani, D., Cross, J. L., Anderton, R. S., Blacker, D. J., Knuckey, N. W., & Meloni, B. P. (2017). Delayed 2-h post-stroke administration of R18 and NA-1 (TAT-NR2B9c) peptides after permanent and/or transient middle cerebral artery occlusion in the rat. Brain Research Bulletin, 135, 62-68.
    • Milani, D., Cross, J. L., Anderton, R. S., Blacker, D. J., Knuckey, N. W., & Meloni, B. P. (2017). Neuroprotective efficacy of poly-arginine R18 and NA-1 (TAT-NR2B9c) peptides following transient middle cerebral artery occlusion in the rat. Neuroscience Research, 114, 9-15.
    • Meloni, B. P., Milani, D., Cross, J. L., Clark, V. W., Edwards, A. B., Anderton, R. S., Blacker, D. J., & Knuckey, N. W. (2017). Assessment of the neuroprotective effects of arginine-rich protamine peptides, poly-arginine peptides (R12-cyclic, R22) and arginine–tryptophan-containing peptides following in vitro excitotoxicity and/or permanent middle cerebral artery occlusion in rats. NeuroMolecular Medicine, 19(2), 271-285.
    • MacDougall, G., Anderton, R. S., Edwards, A. B., Knuckey, N. W., & Meloni, B. P. (2017). The neuroprotective peptide poly-arginine-12 (R12) reduces cell surface levels of NMDA NR2B receptor subunit in cortical neurons; investigation into the involvement of endocytic mechanisms. Journal of Molecular Neuroscience, 61(2), 235-246.
    • Joyce, C., Hine, G., & Anderton, R. (2017). The association between secondary mathematics and first year university performance in health sciences. Issues in Educational Research, 27(4), 770-783.
    • Evans, T., Jefferson, A., Byrnes, M., Walters, S., Ghosh, S., Mastaglia, F. L., Power, B., & Anderton, R. S. (2017). Extended “Timed Up and Go” assessment as a clinical indicator of cognitive state in Parkinson's disease. Journal of the neurological sciences, 375, 86-91.
    • Edwards, A. B., Feindel, K. W., Cross, J. L., Anderton, R. S., Clark, V. W., Knuckey, N. W., & Meloni, B. P. (2017). Modification to the Rice-Vannucci perinatal hypoxic-ischaemic encephalopathy model in the P7 rat improves the reliability of cerebral infarct development after 48 hours. Journal of neuroscience methods, 288, 62-71.
    • Edwards, A. B., Anderton, R. S., Knuckey, N. W., & Meloni, B. P. (2017). Characterisation of neuroprotective efficacy of modified poly-arginine-9 (R9) peptides using a neuronal glutamic acid excitotoxicity model. Molecular and Cellular Biochemistry, 426(1), 75-85.
    • Edwards, A., Feindel, K., Cross, J., Anderton, R., Clark, V., Knuckey, N., & Meloni, B. (2017). Neuroprotective efficacy of poly-arginine-18 (R18) peptides using an in vivo model of perinatal hypoxic ischaemic encephalopathy (HIE). Journal of Cerebral Blood Flow and Metabolism, 37, 18-19.
    • Chiu, L. S., Anderton, R. S., Knuckey, N. W., & Meloni, B. P. (2017). Peptide pharmacological approaches to treating traumatic brain injury: a case for arginine-rich peptides. Molecular Neurobiology, 54(10), 7838-7857.
    • Chiu, L. S., Anderton, R. S., Cross, J. L., Clark, V. W., Edwards, A. B., Knuckey, N. W., & Meloni, B. P. (2017). Assessment of R18, COG1410, and APP96-110 in excitotoxicity and traumatic brain injury. Translational Neuroscience, 8(1), 147-157.
    • Anderton, R. S., Hill, L., Morris, R., Mastaglia, F. L., Greene, W., & Boulos, S. (2017). Lack of evidence for decreased protein stability in the 2397 (Met) haplotype of the leucine rich repeat kinase 2 protein implicated in Parkinson’s disease. Advances in Parkinson's Disease, 6.
    • Anderton, R. S., Byrnes, M., Jefferson, A., Walters, S., Ghosh, S., Stell, R., & Mastaglia, F. L. (2017). Sleep Disturbance and Serum Ferritin Levels Associate with High Impulsivity and Impulse Control Disorders in Male Parkinson’s Disease Patients. American Journal of Psychiatry and Neuroscience, 5(4), 45-52.
    • Anderton, R. S. (2017). Identifying factors that contribute to academic success in first year allied health and science degrees at an Australian university. Australian Journal of Education, 61(2), 184-199.
    • Anderton, R., Hine, G., & Joyce, C. (2017). Secondary school mathematics and science matters: Predicting academic success for secondary students transitioning into university allied health and science courses. International Journal of Innovation in Science and Mathematics Education, 25(1).
    • Milani, D., Knuckey, N. W., Anderton, R. S., Cross, J., & Meloni, B. P. (2016). The R18 polyarginine peptide is more effective than the TAT-NR2B9c (NA-1) peptide when administered 60 minutes after permanent middle cerebral artery occlusion in the rat. Stroke Research and Treatment, 2016.
    • Milani, D., Clark, V. W., Cross, J. L., Anderton, R. S., Knuckey, N. W., & Meloni, B. P. (2016). Poly-arginine peptides reduce infarct volume in a permanent middle cerebral artery rat stroke model. BMC neuroscience, 17(1), 1-8.
    • Jacob, Y., Cripps, A., Evans, T., Chivers, P. T., Joyce, C., & Anderton, R. S. (2016). Identification of genetic markers for skill and athleticism in sub-elite Australian football players: a pilot study. The Journal of sports medicine and physical fitness, 58(3), 241-248.
    • Chiu, L. S., Anderton, R. S., Knuckey, N. W., & Meloni, B. P. (2016). The neuroprotective potential of arginine-rich peptides for the acute treatment of traumatic brain injury. Expert review of neurotherapeutics, 16(4), 361-363.
    • Anderton, R. S., Chiu, L. S., & Aulfrey, S. (2016). Student Perceptions to Teaching Undergraduate Anatomy in Health Sciences. International Journal of Higher Education, 5(3), 201-216.
    • Anderton, R., & Chivers, P. (2016). Predicting academic success of health science students for first year anatomy and physiology. International Journal of Higher Education, 5(1).
    • Meloni, B. P., Milani, D., Edwards, A. B., Anderton, R. S., Doig, R. L. H., Fitzgerald, M., Palmer, T. N., & Knuckey, N. W. (2015). Neuroprotective peptides fused to arginine-rich cell penetrating peptides: Neuroprotective mechanism likely mediated by peptide endocytic properties. Pharmacology & Therapeutics, 153, 36-54.
    • Meloni, B. P., Brookes, L. M., Clark, V. W., Cross, J. L., Edwards, A. B., Anderton, R. S., Hopkins, R. M., Hoffmann, K., & Knuckey, N. W. (2015). Poly-arginine and arginine-rich peptides are neuroprotective in stroke models. Journal of Cerebral Blood Flow & Metabolism, 35(6), 993-1004.
    • Anderton, R. S., & Mastaglia, F. L. (2015). Advances and challenges in developing a therapy for spinal muscular atrophy. Expert review of neurotherapeutics, 15(8), 895-908.
    • Kanyenda, L. J., Verdile, G., Martins, R., Meloni, B. P., Chieng, J., Mastaglia, F., Laws, S. M., Anderton, R. S., & Boulos, S. (2014). Is cholesterol and amyloid-β stress induced CD147 expression a protective response? Evidence that extracellular cyclophilin a mediated neuroprotection is reliant on CD147. Journal of Alzheimer's disease, 39(3), 545-556.
    • Anderton, R., Meloni, B., Mastaglia, F., & Boulos, S. (2014). Investigation of a recombinant SMN protein delivery system to treat spinal muscular atrophy. Translational Neuroscience, 5(1), 8-16.
    • Anderton, R. S., Meloni, B. P., Mastaglia, F. L., & Boulos, S. (2013). Spinal muscular atrophy and the antiapoptotic role of survival of motor neuron (SMN) protein. Molecular Neurobiology, 47(2), 821-832.
    • Anderton, R., Price, L., Turner, B., Meloni, B., Mitrpant, C., Mastaglia, F., Goh, C., Wilton, S., & Boulos, S. (2012). Co-regulation of survival of motor neuron and Bcl-xL expression: implications for neuroprotection in spinal muscular atrophy. Neuroscience, 220, 228-236.
    • Anderton, R., Meloni, B., Mastaglia, F., Greene, W., & Boulos, S. (2011). Survival of motor neuron protein over-expression prevents calpain-mediated cleavage and activation of procaspase-3 in differentiated human SH-SY5Y cells. Neuroscience, 181, 226-233.

  • Conference Papers

    • Hine, G., Anderton, R., & Joyce, C. (2015). Mathematics: A good predictor for success in a health science degree. Proceedings of The Australian Conference on Science and Mathematics Education